Proteonomix understands; today it takes neighborhood to develop a cure

PRLog (Press Release) - Jul 22, 2010 -
Proteonomix (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site,
Proteonomix operates like an umbrella with several subsidiaries that are working in different areas to bring a variety of modalities to market.
Proteoderm.com, begun accepting pre-orders for its anti-aging line of skin care products.
StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use.


National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

Proteonomix is proving that good things grow in Mountainside, New Jersey, not just in the summer but all year long.

The company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market.

Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.

In tandem with this, the company will also be launching a genetic diversity program to increase the currently under-represented minority groups in the pool of available cord blood stem cell units.

Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/,

Michael Cohen, Chairman and CEO of Proteonomix said "The mission of one of our subsidiaries, Proteonomix Regenerative Translational Medicine Institute, Inc. ('PRTMI'), is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. PRTMI will undertake the creation of a global, single standard, cellular laboratory that will seek to create a seamless transition between laboratories and patient care facilities."





*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************











THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.


*******************************************